EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Enseval Putra Megatrading Tbk (EPMT) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Enseval Putra Megatrading Tbk IDR 4,929, price IDR 2,630, upside +87.4%, quality 60 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · ID · ISIN ID1000096506

EP Thin data Sep 23, 2026

Enseval Putra Megatrading Tbk

EPMT · JK

Clearly undervaluedStrong Fair Value upside, but quality is only moderate.

Fair value 4,929 IDR · Strongly undervalued (+87%)
!Quality 60/100
Healthy Growth (revenue 5y +7.9 %/yr)
!Thin margins · 2.3% net margin (TTM)
Low debt · generates free cash flow
Ranks above peers (13/14)
!Narrow moat 38/100
!Evidence only low, so the estimate is less certain

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

2,650 IDR 1,473 IDR Fair Value 4,929 IDR Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range 1,473 IDR – 2,650 IDR · fair‑value band 3,183 IDR – 6,408 IDR · the 2,630 IDR price screens below the 4,929 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.

Follow Enseval Putra Megatrading Tbk in your weekly email

Every Wednesday you see whether Enseval Putra Megatrading Tbk is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

PT Enseval Putera Megatrading Tbk., together with its subsidiaries, engages in the distribution and supply of pharmaceutical products, consumer products, medical equipment, cosmetics, and other trading products in Indonesia. The company operates through three segments: Pharmaceutical, Consumer Products, and Others.

Show more

PT Enseval Putera Megatrading Tbk., together with its subsidiaries, engages in the distribution and supply of pharmaceutical products, consumer products, medical equipment, cosmetics, and other trading products in Indonesia. The company operates through three segments: Pharmaceutical, Consumer Products, and Others. It also trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, consumable products for hemodialysis therapy, pharmaceutical, medical equipment, and food and beverage; prescription and non-prescription medicines; veterinary products; and operates drug stores, health care clinics, and hemodialysis clinic. In addition, the company provides dental and other equipment; calibration services; distribution and logistics for consumer goods that require cold room temperature handling; transportation and warehousing service using digital platform; information services through web portals and/or digital platforms; healthcare services; end-to-end value added services; and logistic services, including chiller, cool, and ambient rooms, as well as container chiller. Further, it offers EMOS, a business-to-business (B2B) platform that offers pharmaceuticals and consumer health products; and MOSTRANS, an intelligent logistics platform that connects with shippers, transporters, and receivers. The company was formerly known as PT Arya Gupta Cempaka and changed its name to PT Enseval Putera Megatrading Tbk. in August 1993. PT Enseval Putera Megatrading Tbk. was founded in 1973 and is headquartered in Jakarta Timur, Indonesia. PT Enseval Putera Megatrading Tbk. is a subsidiary of PT Kalbe Farma Tbk.

Stock analysis

Enseval Putra Megatrading Tbk (EPMT) currently trades at 2,630 IDR, while our model-based Fair Value estimate is 4,929 IDR, implying the stock looks roughly 46.6% undervalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of 6,202 IDR per share, and 25 of the 26 models we run sit above the 2,630 IDR price.

Bear case: the Asset-Based group reads lowest at 1,935 IDR, and 1 of the 26 models stay below the price. Evidence for this calculation is low.

Scenario range: 3,183 IDR (bear) to 6,408 IDR (bull), the price of 2,630 IDR sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Enseval Putra Megatrading Tbk reported revenue of 33.0T IDR in FY2025 versus 25.7T IDR in FY2021, a compound +6.4%/yr. Reported net income was 789B IDR in FY2025, compounding −1.8%/yr from FY2021.

Key figures

Market cap 7.1T IDR (≈ $712M) · P/E ratio 9.2 · P/S ratio 0.22 · EPS (TTM) 286.02 IDR · Dividend yield 7.7% · Net margin 2.4% · Return on equity 9.7% · Return on assets (EBIT) 9.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).

What moves the price

The share trades about 1% below its 52-week high and 20% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 87%, EPMT screens cheaper than that median.

Fair Value models

Bear 3,183 IDR Fair Value 4,929 IDR Bull 6,408 IDR
Model Each model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (209.20 IDR per share) are deliberately not added. Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence Evidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF 3,153 IDR 5,217 IDR 8,731 IDR 78
Growth DCF 3,180 IDR 5,210 IDR 8,699 IDR 76
Residual Income 2,597 IDR 2,903 IDR 4,575 IDR 75
All 26 models by family
DCF Models
FCF DCF 3,153 IDR 5,217 IDR 8,731 IDR 78
Owner Earnings 3,897 IDR 6,492 IDR 10,911 IDR 74
5Y Revenue Exit 3,397 IDR 5,654 IDR 8,639 IDR 71
5Y EBITDA Exit 4,034 IDR 6,902 IDR 10,383 IDR 74
5Y P/E Exit 4,150 IDR 7,130 IDR 10,404 IDR 70
10Y Revenue Exit 3,180 IDR 5,293 IDR 8,349 IDR 65
10Y EBITDA Exit 3,715 IDR 6,202 IDR 9,772 IDR 67
10Y P/E Exit 3,792 IDR 6,368 IDR 9,790 IDR 63
Earnings-Based
Graham-Dodd 1,981 IDR 7,584 IDR 10,274 IDR 64
Lynch FV 1,848 IDR 2,640 IDR 3,432 IDR 61
PEG = 1.0 1,848 IDR 2,640 IDR 3,432 IDR 57
EPV 3,075 IDR 3,571 IDR 4,012 IDR 74
Dividend Discount
Gordon GGM 1,723 IDR 3,761 IDR 6,328 IDR 65
DDM Multi-Stage 1,723 IDR 3,081 IDR 3,920 IDR 66
Multiples
P/E Multiple 4,807 IDR 6,410 IDR 8,012 IDR 63
P/S Multiple 3,715 IDR 4,953 IDR 6,191 IDR 58
P/B Multiple 3,715 IDR 4,953 IDR 6,191 IDR 55
EV/EBIT 4,949 IDR 6,511 IDR 8,074 IDR 66
EV/EBITDA 4,881 IDR 6,420 IDR 7,960 IDR 67
EV/Revenue 3,608 IDR 5,041 IDR 6,475 IDR 54
Asset-Based
NCAV (Graham) 1,444 IDR 1,935 IDR 2,888 IDR 54
Growth DCF
Growth DCF 3,180 IDR 5,210 IDR 8,699 IDR 76
Rev-Margin DCF 3,397 IDR 5,612 IDR 8,305 IDR 72
Economic Profit
Residual Income 2,597 IDR 2,903 IDR 4,575 IDR 75
ROIC Compounder 3,153 IDR 4,151 IDR 5,596 IDR 71
Growth Earnings
Growth-Adj P/E 3,450 IDR 4,929 IDR 6,408 IDR 67

Open the full fair value analysis →

Notify me when EPMT reaches fair value

Put EPMT on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 60/100

Of which business quality 59 · Market factors (momentum, volatility) 71

Profitability 51
Margins and returns on capital today
Quality Growth 36
Are margins and returns improving?
Cashflow 36
Earnings quality: real cash, not paper profit
Fin. Strength 82
Balance sheet, leverage, solvency risk
Investment 81
Disciplined investing over empire-building
Low Volatility 96
Calm price path (market factor)
Momentum 54
Price trend over the last 3–12 months (market factor)
52W Momentum 73
Distance to the 52-week high (market factor)
Net Issuance 82
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality Growth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 71/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+6.5%
Revenue growth 3 years Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.6%
Revenue growth 5 years Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.9%
Start year 2020 (pandemic). Over 10 years: +6.6% a year
Revenue growth 25 years Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.7%
What shareholders gained per year (last 5 years), in IDR What the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in IDR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+10.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+3.0%
Dividend (yield on the price)7.7%
Pace: 5 vs 10 years Two data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.3% vs 4%, steady
Profit margin 2020 to 2025 Operating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.4% → 3%
Start year 2020 (pandemic)

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes This turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+0.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Indonesia: IMF forecast 2.6% a year to 2030, 2.9% from 2016 to 2025) that is about −1.7% a year for the price.

Watch EPMT, get fair value alerts →

Compare Enseval Putra Megatrading Tbk with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 81 stocks

Beats the industry median on 12/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 60 · Top 25%
Fair Value upside +87% · Top 25%
Profitability
Return on equity (TTM) 10% · Above median
Return on assets 5% · Top 25%
Net margin (TTM) 2% · Above median
Operating margin (TTM) 4% · Above median
Growth and dividend
Revenue growth 9% · Top 25%
Dividend yield (TTM) 7.7% · Top 25%

Valuation Multiplesvs Medical Distribution median · lower = cheaper

P/E (TTM) 9.2× · Cheapest 25%
P/B 0.91× · Pricier than median
P/S (TTM) 0.21× · Cheaper than median
P/FCF 0.0× · Cheapest 25%
EV/EBITDA 5.4× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 34
FUTURE (revenue growth)45 · sector 18
PAST (return on equity)39 · sector 27
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)100 · sector 59

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
McKesson Corporation MCK $891.23 $819.31 −8%
Cencora, Inc COR $314.43 $211.07 −33%
Cardinal Health, Inc CAH $222.04 $141.77 −36%
Henry Schein, Inc HSIC $87.43 $76.86 −12%
Shanghai Pharmaceuticals Holding 601607 ¥16.04 ¥42.67 +166%
Galenica AG GALE CHF 83.45 CHF 61.79 −26%
Guangzhou Baiyunshan Pharmaceutical Holdings 600332 ¥19.68 ¥27.98 +42%
Jointown Pharmaceutical Group 600998 ¥4.87 ¥9.84 +102%
China National Medicines Corporation 600511 ¥26.12 ¥58.47 +124%
Asker Healthcare Group ASKER kr 59.15 kr 28.26 −52%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Enseval Putra Megatrading Tbk Fair Value". https://www.fairvalue-calculator.com/stock/EPMT

Frequently asked questions

Is Enseval Putra Megatrading Tbk (EPMT) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of 4,929 IDR versus a price of 2,630 IDR, about +87% upside (undervalued).
What is the fair value of EPMT?
Our model-based fair value for Enseval Putra Megatrading Tbk is 4,929 IDR (as of Sep 23, 2026), built from audited fundamentals. The current price: 2,630 IDR.
What is the quality score of EPMT?
Enseval Putra Megatrading Tbk has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Enseval Putra Megatrading Tbk (EPMT)?
Our model-based price target is the fair value of 4,929 IDR (as of Sep 23, 2026) from 26 valuation models. Cautious scenario 3,183 IDR, optimistic scenario 6,408 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the Enseval Putra Megatrading Tbk stock forecast for 2026?
Our models put fair value at 4,929 IDR, about +87% upside versus a price of 2,630 IDR (undervalued). Cautious scenario 3,183 IDR, optimistic scenario 6,408 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of Enseval Putra Megatrading Tbk (EPMT)?
Enseval Putra Megatrading Tbk reported trailing-twelve-month revenue of about 33.7T IDR (latest available figure, as of Sep 23, 2026).
Does Enseval Putra Megatrading Tbk pay a dividend?
Enseval Putra Megatrading Tbk currently shows a dividend yield of about 7.69% relative to its recent price (as of Sep 23, 2026).
What growth is priced into Enseval Putra Megatrading Tbk (EPMT)?
For today's price to be fair in a discounted-cash-flow model, Enseval Putra Megatrading Tbk would have to grow free cash flow by +0.8 % per year for five years (discount rate 11.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +7.9 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of EPMT use?
Our models discount Enseval Putra Megatrading Tbk at 11.0 %: a base by market capitalisation (mega), country premium for Indonesia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Enseval Putra Megatrading Tbk that is +0.8 % per year a year over ten years, using the same discount rate (11.0 %) and the same formula as our fair value.
How much growth has Enseval Putra Megatrading Tbk (EPMT) delivered so far?
Over the past 5 years revenue at Enseval Putra Megatrading Tbk grew +7.9 % a year. The price currently implies +0.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Enseval Putra Megatrading Tbk (EPMT) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Enseval Putra Megatrading Tbk (+0.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Enseval Putra Megatrading Tbk (EPMT)?
The free-cash-flow yield on the price is 8.41 %: that much free cash flow Enseval Putra Megatrading Tbk produces per unit of market value. When it exceeds the discount rate of our models (11.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Enseval Putra Megatrading Tbk (EPMT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Enseval Putra Megatrading Tbk it is 4,929 IDR per share (as of Sep 23, 2026), against a price of 2,630 IDR. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Enseval Putra Megatrading Tbk stock overvalued or undervalued in 2026?
As of Sep 23, 2026, EPMT trades below its calculated fair value: price 2,630 IDR, fair value 4,929 IDR, a gap of about +87% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EPMT?
No. The price is what the market pays today (2,630 IDR); the fair value is what the company's own numbers justify (4,929 IDR). For Enseval Putra Megatrading Tbk the two are 2,299 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is Enseval Putra Megatrading Tbk worth?
The market values Enseval Putra Megatrading Tbk at about 7.1T IDR (market capitalisation, as of Sep 23, 2026). Per share that is 2,630 IDR; our models calculate a fair value of 4,929 IDR per share.
What do the bullish and bearish scenarios say about EPMT?
Our models span a range for Enseval Putra Megatrading Tbk: cautious scenario 3,183 IDR, base 4,929 IDR, optimistic 6,408 IDR per share (as of Sep 23, 2026, price 2,630 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of EPMT?
Enseval Putra Megatrading Tbk trades at a price-to-earnings ratio of 9.2 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 4,929 IDR is built from several models across several years. Other multiples: P/B 0.9, P/S 0.2, EV/EBITDA 5.4.
How solid is the balance sheet of Enseval Putra Megatrading Tbk (EPMT)?
Balance-sheet figures for Enseval Putra Megatrading Tbk (as of Sep 23, 2026): return on equity 9.7%. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is EPMT from its 52-week high?
Enseval Putra Megatrading Tbk trades at 2,630 IDR, about 1% below its 52-week high of 2,650 IDR and 20% above the low of 2,200 IDR (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 4,929 IDR is for.
Which stocks are comparable to Enseval Putra Megatrading Tbk?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Enseval Putra Megatrading Tbk stock attractive at the current price?
The data as of Sep 23, 2026: price 2,630 IDR, calculated fair value 4,929 IDR (+87%), Quality Score 60/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EPMT calculated?
We run Enseval Putra Megatrading Tbk through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 4,929 IDR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Enseval Putra Megatrading Tbk currently trades 87 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Enseval Putra Megatrading Tbk (EPMT)?
The closing price on Sep 23, 2026 was 2,630 IDR. Our model-based fair value is 4,929 IDR, about +87% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Enseval Putra Megatrading Tbk right now?
The price is below even our cautious bear case (3,183 IDR). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (60/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (3,183 IDR to 6,408 IDR) leaves room in how you read the outcome.
Where does the earnings growth of Enseval Putra Megatrading Tbk (EPMT) come from?
Earnings per share at Enseval Putra Megatrading Tbk grew +3.6 % a year from 2014 to 2025. Broken into its drivers: revenue per share +6.3 %, EBIT margin −2.8 %, tax rate +0.4 %, residual (interest, one-offs) −0.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Enseval Putra Megatrading Tbk

How large is the market capitalisation of Enseval Putra Megatrading Tbk (EPMT)?
The market capitalisation of Enseval Putra Megatrading Tbk is 7.1T IDR (≈ $712M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Enseval Putra Megatrading Tbk (EPMT)?
The price-to-sales ratio of Enseval Putra Megatrading Tbk is 0.22 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Enseval Putra Megatrading Tbk (EPMT)?
Earnings per share at Enseval Putra Megatrading Tbk are 286.02 IDR (price ÷ EPS = P/E 9.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Enseval Putra Megatrading Tbk (EPMT)?
The dividend yield of Enseval Putra Megatrading Tbk is 7.7% (payout 70.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Enseval Putra Megatrading Tbk (EPMT)?
The net margin of Enseval Putra Megatrading Tbk is 2.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Enseval Putra Megatrading Tbk (EPMT)?
The return on equity (ROE) of Enseval Putra Megatrading Tbk is 9.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Enseval Putra Megatrading Tbk (EPMT)?
On an EBIT basis the return on assets of Enseval Putra Megatrading Tbk is 9.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Enseval Putra Megatrading Tbk (EPMT)?
The operating margin of Enseval Putra Megatrading Tbk is 3.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Enseval Putra Megatrading Tbk (EPMT)?
Revenue at Enseval Putra Megatrading Tbk is growing +9.0% versus a year earlier (3y avg +5.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Enseval Putra Megatrading Tbk (EPMT)?
Earnings per share at Enseval Putra Megatrading Tbk are growing −4.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Enseval Putra Megatrading Tbk (EPMT) hold?
Enseval Putra Megatrading Tbk holds more cash than debt, 522B IDR net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Enseval Putra Megatrading Tbk in the live analysis

One click puts Enseval Putra Megatrading Tbk on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.